Calimmune Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $416M

  • Investors
  • 1

Calimmune General Information

Description

Developer of a gene modification and cell delivery technology based in Tucson, Arizona. The company's technology works by genetically modifying patients' own cells to shield and strengthen their immune systems and create enduring and life-long protection for individuals living with a broad range of debilitating and currently incurable diseases, enabling physicians to address the unique needs of individuals at different stages of HIV infection and with various treatment histories and offering effective and accessible products that have the power to restore health and improve lives.

Contact Information

Website
www.calimmune.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 5151 East Broadway Boulevard
  • Suite 1020
  • Tucson, AZ 85711
  • United States
+1 (310)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Healthcare Technology Systems
Acquirer
CSL
Vertical(s)
Life Sciences
Corporate Office
  • 5151 East Broadway Boulevard
  • Suite 1020
  • Tucson, AZ 85711
  • United States
+1 (310)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 28-Aug-2017 $416M Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) Completed Clinical Trials - Phase 2
7. Later Stage VC (Series B) 27-May-2015 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series A) 01-Dec-2013 Completed Clinical Trials - Phase 2
5. Later Stage VC 01-Oct-2012 Completed Generating Revenue
4. Early Stage VC 16-Sep-2011 Completed Generating Revenue
3. Angel (individual) 01-Jun-2010 Completed Startup
2. Grant $8.28M Completed Startup
1. University Spin-Out 01-Jan-2006 Completed Startup
To view Calimmune’s complete valuation and funding history, request access »

Calimmune Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
Series 4
Series 3
Series 2 107,000 $0.001000 8% $4.94 $4.94 1x $4.94 0.85%
Series 1 188,136 $0.001000 8% $5 $5 1x $5 1.49%
To view Calimmune’s complete cap table history, request access »

Calimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene modification and cell delivery technology based in Tucson, Arizona. The company's technology works b
Biotechnology
Tucson, AZ
3 As of 2023

Phoenix, AZ
 

Lake Forest, IL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Calimmune Competitors (77)

One of Calimmune’s 77 competitors is Amnio Technology, a Accelerator/Incubator Backed company based in Phoenix, AZ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amnio Technology Accelerator/Incubator Backed Phoenix, AZ
Jaguar Gene Therapy Venture Capital-Backed Lake Forest, IL
Casma Therapeutics Venture Capital-Backed Cambridge, MA
Coave Therapeutics Venture Capital-Backed Paris, France
Anokion Venture Capital-Backed Ecublens, Switzerland
You’re viewing 5 of 77 competitors. Get the full list »

Calimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Calimmune Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
California Institute for Regenerative Medicine Government
Cycad Group Venture Capital Minority
DVI Equity Partners Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Calimmune FAQs

  • When was Calimmune founded?

    Calimmune was founded in 2006.

  • Where is Calimmune headquartered?

    Calimmune is headquartered in Tucson, AZ.

  • What is the size of Calimmune?

    Calimmune has 3 total employees.

  • What industry is Calimmune in?

    Calimmune’s primary industry is Biotechnology.

  • Is Calimmune a private or public company?

    Calimmune is a Private company.

  • What is the current valuation of Calimmune?

    The current valuation of Calimmune is .

  • What is Calimmune’s current revenue?

    The current revenue for Calimmune is .

  • How much funding has Calimmune raised over time?

    Calimmune has raised $19.9M.

  • Who are Calimmune’s investors?

    AbbVie Ventures, Alexandria Venture Investments, California Institute for Regenerative Medicine, Cycad Group, and DVI Equity Partners are 5 of 8 investors who have invested in Calimmune.

  • Who are Calimmune’s competitors?

    Amnio Technology, Jaguar Gene Therapy, Casma Therapeutics, Coave Therapeutics, and Anokion are some of the 77 competitors of Calimmune.

  • When was Calimmune acquired?

    Calimmune was acquired on 28-Aug-2017.

  • Who acquired Calimmune?

    Calimmune was acquired by CSL.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »